Changing Haemophilia is Novo Nordisk's commitment to address the
unmet needs in haemophilia care, beyond medicine
Haemophilia is a rare and serious disease
Haemophilia
is a rare and serious disease affecting approx. 1 out of 10,000
people around the world. Many people with haemophilia are still
undiagnosed or inadequately treated. Even when treated, people may
suffer from chronic pain and limited mobility mainly due to bleeds
in the joints, and if undertreated or not treated at all, risk dying
at a young age.
Driving change in haemophilia
Since Novo Nordisk was
founded more than 90 years ago, we have been driving change to
defeat chronic conditions. This includes three decades of improving
lives of people with haemophilia through support to improved
diagnosis, treatment and care.
Our key contribution
Our key contribution is to
discover and develop effective and safe medicines for people with
haemophilia and other rare bleeding disorders. We offer a broad and
innovative range of products and have a rich research/development
pipeline to ensure we are in the forefront of finding the next
generation of medicines.
Addressing unmet needs beyond medicine
But to truly
change haemophilia, we need to do more than supply the right
medicines. With our Changing Haemophilia™ commitment we aim to
address the unmet needs in haemophilia. Together with our community
partners, we work to advocate for, and create better access to,
diagnosis and multidisciplinary care. We aim for better joint health
and mobility including a strong focus on well-being for people
living with haemophilia.
We work towards a future where
everyone with Haemophilia is diagnosed. and can live a life with as
few limitations as possible.
Our three focus areas are:
• Science. Find
out more
• Awareness and access to care. Find
out more
• Joint
outcomes. Find
out more
